To recover your password please fill in your email address
Please fill in below form to create an account with us
Single arm, open label, signal seeking, phase IIa trial of the activity of larotrectinib in patients with advanced NTRK1-3 positive tumours.
|
Trial Summary: |
The aim of this MoST substudy is to assess the clinical activity of Larotrectinib in a population of patients with advanced tumours harbouring NTRK1-3 rearrangements in (i) primary central nervous system (CNS) tumours and (ii) non-CNS cancers. |
|
Supported By: |
|
|
Eligibility: |
Participants will be enrolled in the MoST program for molecular screening and be eligible for this substudy if a somatic NTRK1-3 rearrangement is identified in their tumour. |
|
Registration ID: |
|
|
Participation: |
National |
|
Status: |
In follow-up |
|
Activation Date: |
2/11/2020 |
|
Chairs: |
Dr Subotheni Thavaneswaran |
|
Contact: |